Previous studies showed that hsa-miR-326 inhibited SMO expression in glioma cancer and CD34(+) chronic myeloid leukemia cells and acted as a tumor suppressor miRNA by inhibiting the PI3 kinase pathway in glioblastomas [45–47]. The gene discussed is CD34; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.